Global Paclitaxel Revenue Is Nearly 80 M USD In 2017
Friday, 30 Nov, 2018
In the last several years, global market of Paclitaxel developed rapidly, with an average growth rate of 12.3%. In 2017, global revenue of Paclitaxel is nearly 80 M USD; the actual production is about 2600 Kg.

The classification of Paclitaxel includes Natural Paclitaxel API and Sem-synthetic Paclitaxel API, and the proportion of Natural Paclitaxel API in 2017 is about 31.3%, and the proportion is decreasing trend from 2012 to 2017.

Paclitaxel is widely sales for Ovarian Cancer, Cervical Cancer, Breast?Cancer and Others. The most proportion of Paclitaxel is sales in Ovarian?Cancer, and the consumption proportion is about 46% in 2017.

North America is the largest consumption place, with a consumption market share nearly 52.3% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 19.6%, China is also an important sales region for the Paclitaxel.

Market competition is intense. Phyton, ScinoPharm, Novasep, Samyang, etc. are the leaders of the industry. They hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.